Needham & Company Reiterates Strong Buy Rating on Genomic Health Inc. (GHDX) Ahead of German Coverage Decision
Tweet Send to a Friend
Needham & Company analyst Stephen Unger reiterated a Strong Buy rating and $69.00 price target on Genomic Health Inc. (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
